Sarcomas account for 3% of all uterine malignancies and many of them are characterized by acquired, specific fusion genes whose detection has increased pathogenetic knowledge and diagnostic precision.
mas can be classified unambiguously and meaningfully based on a distinctive histology and/or immunophenotype, some show overlapping features. 3 It is now known that cytogenetic and molecular analyses may help diagnose and classify such tumors. 4, 5 This is because many uterine sarcomas are associated with recurrent chromosomal rearrangements leading to highly specific, tumorigenic gene fusions. The use in recent years of next generation sequencing (NGS) methodology has played an important role in identifying such molecular rearrangements. By way of example, NGS identified a YWHAE-NUTM2 fusion brought about by a 10;17-translocation and a ZC3H7B-BCOR caused by an X;22-translocation in ESS, thus adding two new pathogenetic subgroups to this spectrum of tumors. 6, 7 The identification of specific fusion transcripts is especially important in tumors that are phenotypically difficult to classify. In the present study,
we report the molecular consequences of a translocation t(2;8)(p25;q13)
identified in an undifferentiated uterine sarcoma. High-Throughput
Paired-End RNA-Sequencing revealed that it led to a novel fusion transcript between the Growth Regulation by Estrogen in Breast cancer 1 
| Cell Culturing and Karyotyping
Short-term cultured cells from the lung metastasis surgically removed in 1999 were analyzed cytogenetically as part of our diagnostic routine. 8 The karyotyping followed the recommendations of the International System for Human Cytogenomic Nomenclature (ISCN). 9 The tumor's cytogenetic features have previously been published. 
| Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Sanger Sequencing
The primers used for PCR reactions and Sanger sequencing are listed in Table 1 . For RT-PCR, one mg of total RNA was reverse-transcribed in a 20 ml reaction volume using iScript Advanced cDNA synthesis Kit according to the manufacturer's instructions (Bio-Rad Laboratories, were used for computer analysis of sequence data. 
| R E SU LTS
The cytogenetic investigation of the uterine sarcoma cells showed an abnormal karyotype described as 45,XX,t(2;8)(p25;q13),-8,inv (11) (p15q23),del(14)(q22q32),der(17)t(8;17)(q11;p13) [20] (Figure 2A ).
The FusionCatcher software, with the FASTQ files obtained from the Genomics Core Facility, Oslo University Hospital and University of Oslo (http://oslo.genomics.no/), was used to detect fusion transcripts in the lung metastasis (1999) of the uterine sarcoma. A total of six chimeric transcripts were obtained by the algoritm (Table 2 ). All fusions were tested using the BLAT command (https://genome-euro.ucsc.edu/ cgi-bin/hgBlat?command5start the program) to identify those with 100% identity in the genome according to the UCSC Genome Browser (update Dec. 2013, GRCh38/hg38). Only two of six transcripts showed such identity: GREB1-NCOA2 and its reciprocal NCOA2-GREB1.
To validate the presence of the GREB1-NCOA2 and NCOA2-GREB1 fusions, RT-PCR with specific primers was performed, followed by Sanger sequencing. The presence of an in-frame GREB1-NCOA2
was confirmed, whereas the reciprocal NCOA2-GREB1 fusion was not identified by RT-PCR. Sanger sequencing analysis of the amplified fragment GREB1-NCOA2 showed presence of a fusion between exon 3 of GREB1 (accession number NM_014668.3) and exon 15 of NCOA2
(accession number NM_001321703.1; Figure 2B ,C). The GREB1 and NCOA2 genes map to chromosomal bands 2p25 and 8q13, respectively, making it overwhelmingly likely that the fusion was brought about by the t(2;8)(p25;q13). Since the fusion transcript was identified in the lung metastasis, we tested also the primary tumor and found the same fusion (data not shown).
| D I SCUSSION
The identification of specific fusion transcripts coming from tumorspecific chromosomal aberrations has proven essential in the differential diagnosis of many sarcomas, for example, synovial sarcoma and myxoid liposarcoma, 11, 12 nci.nih.gov/Chromosomes/Mitelman), GREB1 was previously found involved in various types of neoplasia and with different partners: a GREB1-E2F6 fusion was seen in T-cell acute lymphoblastic leukemia 15 and a GREB1-PDE1A in adenocarcinoma of the prostate. 16 Although its exact function in the cascade of hormone action remains unclear, GREB1 may regulate proliferation in hormone responsive ovarian and endometrial cancer cells and thus be a candidate for further consideration as a potential therapeutic target.
17
NCOA2, which maps to chromosomal band 8q13, is a member of the p160 steroid receptor coactivator gene family. 18 It interacts with ligand-bound nuclear receptor through its nuclear receptor interaction domain (NID) and C-terminal transcriptional activation domains, AD1/ CID (activation domain 1/CREB-binding protein interacting domain) and AD2, to recruit histone acetyltransferases and methyltransferases to specific enhancer/promoter regions, thereby facilitating chromatin remodeling and transcription of nuclear receptor target genes. however; in SRF-NCOA2 it involves exon 12, in HEY1-NCOA2 and TEAD1-NCOA2 exon 13, in VGLL2-NCOA2 and GTF2-NCOA2 exon 14, and in ETV6-NCOA2, PAX3-NCOA2, and AHRR-NCOA it is in exon 15.
The fusion transcript GREB1-NCOA2 is in-frame coding for a chimeric protein that retains the interval 116-207 amino acids of GREB1 (NP_055483) and the nuclear receptor coactivator domain (amino acids 1071-1399) from the C-terminal part of NCOA2 (NP_006531). The nuclear receptor coactivator from NCOA2 contains the AD1/CID and AD2 domains that seem to be essential for the transformation capacity of various cancer gene fusions (Figure 2 D) . 29, 30 The fusion GREB1-NCOA2 has not been previously reported, but one of the genes involved, NCOA2, is known to play a role in transcriptional regulation 19 which probably holds a key to its contribution to the tumorigenic and/or progression process. The importance of such chimeric transcripts is well documented in endometrial stromal sarcomas via the fusions JAZF1-SUZ12, JAZF1-PHF1, EPC1-PHF1, MEAF6-PHF1, ZC3H7B-BCOR, and possibly also MBTD-Cxorf67, whose presumed oncogenic effects are mediated through altered transcriptional control. 31 The karyotype contained also other structural rearrangements of chromosomes, but no fusion transcript(s) were found involving gene(s)
mapping to the other breakpoints. This is strong, albeit indirect, evidence that the translocation t(2;8)(p25;q13) generated the essential 
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